Talk through intended use + pilot scope

See how Fulcrym fits your line.

We’ll walk through intended use, pilot scope, validation path, and ROI assumptions specific to your product and site governance.

Designed for QA, engineering, and site leadership. Positioned as decision support. Final authority remains with QA.

30 minutes, structured, no theatrics. You leave with a clear next step.

1) Understand your line Product type, inspection flow, defect profile, and where ambiguity shows up.
2) Define intended use Parallel vs line-adjacent, validation footprint, and change-control fit.
3) Review pilot path + ROI Success criteria, evidence outputs, and your site-specific ROI assumptions.

Who this is for

This conversation is typically relevant if you operate solid oral dose lines and inspection outcomes are creating cost, risk, or QA friction.

Tablets or capsules where inspection drives release confidence and downstream quality outcomes.

Reject trends that don’t match upstream process reality, or cases that require repeat review.

Inspection-driven deviations, repeat narratives, and teams spending time proving what happened.

Risk reversal: We can start in parallel mode to generate evidence and compare outcomes without disrupting validated release workflows.

Share a few details so we can route the conversation correctly (QA, engineering, ops, or leadership).

Name

Work email

Company

Role

Manufacturing type

Primary interest

Estimated line count (optional)

If unknown, leave blank. A rough estimate helps for scoping.

Desired timeline (optional)

This is used only to prioritize scheduling.

Message (optional)

If you prefer, paste a brief description of your current inspection flow and what’s painful.

Review ROI framing

By submitting, you agree that Fulcrym may contact you about this request. No spam, no mailing list ambush.

Here’s what we typically ask for and what you should expect back.

Want the template now? Use the form and select Pilot evaluation. We’ll send the scope outline and success-criteria format.

Read the short technical briefs, then come back here with your intended use and governance questions.